Radiopharm Theranostics Prices A$6.13M Tranche 1 of Australian Placement at A$0.015/Share
RADX is trading near its 52-week low of $2.73 (9.9% above the low).
Summary
Radiopharm Theranostics priced the first tranche of its Australian placement, issuing 408.8 million shares at A$0.015 each to raise A$6.13 million, with more securities to come, as the company fights to extend its cash runway.
Key Events · Financing and Capital Events · RADX
-
Tranche 1 Placement Priced
408,839,531 ordinary shares issued at A$0.015 each, raising approximately A$6.13 million.
-
Further Dilution Ahead
40 million more shares, 448.8 million options (EX A$0.018), and 1.3 million ADR warrants remain to be issued, adding significant overhang.
-
Cash Runway Critical
The company had only A$4.1 million in cash and 0.28 quarters of runway as of Q2 2026; this placement is essential to fund operations.
-
Deep Discount to Market
The A$0.015 issue price is a steep discount to the US$3.00 ADS price, reflecting the company's distressed financing position.
Analysis · RADX · Life Sciences
Radiopharm Theranostics is issuing 408.8 million shares at A$0.015 each, raising approximately A$6.13 million in the first tranche of its previously announced Australian placement. This follows a series of capital raises in July, including a US$4.1 million registered direct offering and an ATM program. The company's Q2 2026 report revealed only A$4.1 million in cash and 0.28 quarters of runway, so this placement is critical for near-term survival. The filing also discloses that 40 million more shares, 448.8 million options, and 1.3 million ADR warrants are yet to be issued, indicating further dilution ahead. The issue price of A$0.015 represents a significant discount to the current US$3.00 ADS price (each ADS represents a number of ordinary shares, but the exact ratio is not specified here), reflecting the company's distressed position.
At the time of this filing, RADX was trading at $3.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.6M. The 52-week trading range was $2.73 to $16.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.